In the long human effort to keep the brain supplied with blood, a stroke is a moment when a clot cuts off that supply and time becomes the decisive variable. XCath Robotics, a company building robots that work inside blood vessels, has now received the U.S. Food and Drug Administration's Breakthrough Device Designation for its Iris system, which aims to let a surgeon remove such clots from a distance. The recognition follows a March demonstration in which a surgeon in Panama operated the device on a patient more than 120 miles away, a first in a living person. It is a sign that distance, long
XCath's Iris Robot Wins FDA Breakthrough Designation for Remote Stroke Clot Removal
Acute ischemic stroke patients are the population the device targets; no casualties are reported in the source.
A surgeon in Santiago treated a stroke patient more than 120 miles away
In the long human effort to keep the brain supplied with blood, a stroke is a moment when a clot cuts off that supply and time becomes the decisive variable. XCath Robotics, a company building robots that work inside blood vessels, has now received the U.S. Food and Drug Administration's Breakthrough Device Designation for its Iris system, which aims to let a surgeon remove such clots from a distance. The recognition follows a March demonstration in which a surgeon in Panama operated the device on a patient more than 120 miles away, a first in a living person. It is a sign that distance, long a barrier in medicine, may be yielding to careful engineering, though the path from trial to ordinary care remains ahead.
XCath Robotics, a company that builds surgical robots for procedures inside blood vessels, has received Breakthrough Device Designation from the U.S. Food and Drug Administration for its Iris Surgical Robotic System. The device is meant for remote, robot-assisted mechanical thrombectomy, the procedure that removes a clot blocking blood flow to the brain during an acute ischemic stroke. The announcement was made from New Delhi on September 16.
What sets the Iris System apart is distance. The surgeon no longer has to share a room, or even a city, with the patient. That was shown in March 2026 during a clinical investigation called Operation Robo Angel, when neurosurgeon Dr. Vitor Mendes Pereira operated the system from Santiago, Panama, while his patient was at The Panama Clinic in Panama City, more than 120 miles away. XCath describes it as the world's first remote telerobotic mechanical thrombectomy in a living patient.
The FDA's Breakthrough Devices Program supports devices that may treat life-threatening or irreversibly debilitating conditions, and stroke qualifies. For XCath, the designation brings more chances to work with FDA experts and more support through development and review. It is not an approval, and the device is not yet cleared for general use.
XCath's Chief Executive Officer, Eduardo Fonseca, called the designation an important milestone and said the company's investigational cases are already shaping the system, with the goal of extending life-saving stroke care to the many patients it hopes to reach.
The available reporting leaves key questions open: how many patients have received Iris, how the March patient fared, and when a regulatory submission might come. What is clear is the sequence so far, a first-in-human remote procedure followed by formal FDA recognition. What comes next is whether more cases follow, what they show, and whether the Iris System moves beyond trial settings.
XCath Robotics, a company that builds surgical robots for procedures inside blood vessels, has received Breakthrough Device Designation from the U.S. Food and Drug Administration for its Iris Surgical Robotic System. The system is intended for remote, robot-assisted mechanical thrombectomy in patients with acute ischemic stroke. The announcement was distributed from New Delhi on September 16.
Mechanical thrombectomy is the procedure used to remove a clot blocking blood flow to the brain during an ischemic stroke. What the Iris System adds is distance: the surgeon operating the robot does not have to be in the same room, or the same city, as the patient.
That was demonstrated in March 2026, shortly before the designation. In a clinical investigation called Operation Robo Angel, neurosurgeon Dr. Vitor Mendes Pereira operated the Iris System from a control station in Santiago, Panama. His patient was at The Panama Clinic in Panama City, more than 120 miles away. XCath describes it as the world's first remote telerobotic mechanical thrombectomy performed in a living patient.
The FDA's Breakthrough Devices Program exists to support the development of devices that may offer more effective treatment for life-threatening or irreversibly debilitating conditions. Acute ischemic stroke fits that description. For XCath, the practical benefit is more opportunities to interact with FDA experts and to receive support during the regulatory development and review process as it advances the Iris System. The source does not describe the designation as an approval, and it does not say the device is cleared for general use.
Eduardo Fonseca, XCath's Chief Executive Officer, called the designation an important milestone for the company's mission. He said XCath looks forward to continued collaboration with the FDA as the Iris System is developed and evaluated. He also said that real-world learnings from the company's investigational cases are helping shape the system, with the aim of expanding access to life-saving stroke care for the millions of patients the company ultimately hopes to serve.
The source gives no figures on how many patients have been treated with Iris, how the March patient fared, or when a regulatory submission might come. It also names no timeline for wider availability. What it does establish is the sequence: a first-in-human remote procedure in March, followed by formal FDA recognition of the device's potential.
What to watch next is whether further investigational cases follow Operation Robo Angel, what results they show, and whether the regulatory support that comes with the designation moves the Iris System from trial settings toward broader use.
Bemerkenswerte Zitate
The designation is an important milestone for our mission, and real-world learnings from investigational cases are helping shape the system to expand access to life-saving stroke care.— Eduardo Fonseca, CEO of XCath (paraphrased)
Möchten Sie die ganze Geschichte?
Das Original lesen bei ANI (Asian News International) ↗
Health & Medicine